Genprex Inc (GNPX)
NASDAQ:GNPX

Genprex Stock Analysis & Ratings

GNPX Stock Chart & Stats

Day’s Range$1.46 - $1.58
52-Week Range$1.17 - $4.07
Previous Close$1.51
Volume58.76K
Average Volume (3M)671.10K
Market Cap$73.28M
P/E Ratio-3.6
Beta-0.64
Next EarningsAug 13, 2019
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart Score3
EPS (TTM)-0.42


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

GNPX FAQ

What was Genprex’s price range in the past 12 months?
Genprex lowest stock price was $1.17 and its highest was $4.07 in the past 12 months.
    What is Genprex’s market cap?
    Genprex’s market cap is $73.28M.
      What is Genprex’s price target?
      Currently, no data Available
      What do analysts say about Genprex?
      Not enough analysts have published a price target to provide an average price target.
      When is Genprex’s upcoming earnings report date?
      Genprex’s upcoming earnings report date is Aug 13, 2019 which is 1011 days ago.
        How were Genprex’s earnings last quarter?
        Currently, no data Available
        Is Genprex overvalued?
        According to Wall Street analysts Genprex’s price is currently Overvalued.
          Does Genprex pay dividends?
          Genprex does not currently pay dividends.
          What is Genprex’s EPS estimate?
          Genprex’s EPS estimate is -$0.24.
            How many shares outstanding does Genprex have?
            Genprex has 47,900,000 shares outstanding.
              What happened to Genprex’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Genprex?
              Currently, no hedge funds are holding shares in GNPX

              ---

              Genprex Stock Analysis

              Smart Score
              3
              Underperform
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10
              Price Target
              No data currently available
              The Genprex stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
              Learn more about TipRanks Smart Score

              Company Description

              Genprex Inc

              Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Vaxart
              Onconova Therapeutics
              Cocrystal Pharma
              Tonix Pharma
              Co-Diagnostics

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis